

Ref: FOI/GS/ID 5041

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone  
Kent  
ME16 9QQ  
Email: mtw-tr.foiadmin@nhs.net

29 November 2018

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Non-Small Cell Lung Cancer.

*You asked:*

*Please provide the following information relating to NSCLC patients treated by your Trust in the 3 months, July 2018 to September 2018 inclusive. If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.*

*1. Total number treated Stage IIIB/IV NSCLC Patients*

*Patients with NSCLC Stage IIIB/IV (Stage 3b/4)*

*Total number NSCLC patients*

*Other (please specify)*

*Data not held/accessible*

*Of the Stage IIIB/IV NSCLC patients, please indicate the number of patients treated by your Trust in the 3 months July 2018 to September 2018 inclusive, with the following therapies.*

*2. Total number treated Stage IIIB/IV NSCLC Patients. If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:*

*Docetaxel (mono or combination therapy)*

*Atezolizumab (Tecentriq)*

*Nivolumab (Opdivo)*

*Pembrolizumab (Keytruda)*

*3. If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred:*

## Trust Response:

Please provide the following information relating to NSCLC<sup>1</sup> patients treated<sup>2</sup> by your Trust in the 3 months, **July 2018 to September 2018** inclusive.

If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.

	<b>Total number treated</b> Stage IIIB/IV NSCLC Patients	<b>If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:</b>	
Patients with NSCLC Stage IIIB/IV (Stage 3b/4) <sup>3</sup>	18	Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	

Of the Stage IIIB/IV NSCLC patients, please indicate the number of patients treated by your Trust in the 3 months **July 2018 to September 2018** inclusive, with the following therapies.

	<b>Total number treated</b> Stage IIIB/IV NSCLC Patients	<b>If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:</b>	
Docetaxel (mono or combination therapy )		Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	
Atezolizumab (Tecentriq)	4	Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	
Nivolumab (Opdivo)		Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	
Pembrolizumab (Keytruda)		Total number NSCLC patients	
		Other (please specify)	
		Data not held/accessible	

<sup>1</sup> ICD10 C33, C34

<sup>2</sup> Please indicate the number of patients (excluding clinical trial patients) treated with any active anti-cancer drug treatment.

<sup>3</sup> TNM staging for Stage IIIB NSCLC = Any T, N3, M0 or T4, N2, M0; TNM staging for Stage IV NSCLC = Any T, any N, M1

Please include number for both those patients that present at stage III/IV and also those whose cancer has progressed to stage III/IV